Related Experiment Videos
Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised
W Fassbinder1, O Quarder, A Waltz
1Städtisches Klinikum Fulda, Mannheim, Germany.
Insights
Carvedilol effectively reduced microalbuminuria (MAU) in hypertensive patients. This renal protection appeared independent of blood pressure reduction, suggesting a direct kidney benefit.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Essential hypertension is a major risk factor for chronic kidney disease.
- Microalbuminuria (MAU) is an early marker of kidney damage in hypertensive patients.
- Carvedilol is an antihypertensive medication with beta-blocking and vasodilating properties.
Purpose of the Study:
- To evaluate the effect of carvedilol on microalbuminuria (MAU) in patients with essential hypertension.
- To determine if the reduction in MAU is correlated with blood pressure reduction.
- To explore potential renal protective effects of carvedilol.
Main Methods:
- A subset of 876 patients from a larger randomized trial had MAU assessed at baseline and 12 weeks.
- The Micral-Test was used to quantify microalbuminuria.
- Patients received different regimens of carvedilol, with varying blood pressure reductions.
Main Results:
- 28% of patients had MAU at baseline.
- Carvedilol treatment led to significant MAU reduction (54-60%) across all groups.
- Complete MAU disappearance was observed in 48-55% of patients.
- The decrease in MAU did not correlate with the extent of blood pressure reduction.
Conclusions:
- Carvedilol demonstrates a significant beneficial effect on microalbuminuria in hypertensive patients.
- The renal protective effect of carvedilol may be independent of its blood pressure-lowering action.
- These findings suggest carvedilol has direct renal protective properties beyond its antihypertensive effects.
Abstract:
Patients with mild to moderate essential hypertension (n = 1570) were enrolled in a large, multicentre, randomised, open-label study designed to evaluate the safety and efficacy of different regimens of carvedilol. Reported here are the effects of carvedilol on microalbuminuria (MAU) in a subset of 876 patients who underwent MAU assessment (i.e. the Micral-Test) at baseline and at week 12. MAU was present at baseline in 245 (28%) of these patients. Despite different magnitudes of blood pressure reduction, improvements in MAU were similar in all groups (range 54-60%), with complete disappearance occurring in 48-55% of patients. The decrease in MAU did not correlate with the magnitude of blood pressure reduction, suggesting a possible renal protective effect exerted by carvedilol independent of blood pressure reduction mediated by beta-blockade and vasodilatation.